Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced new preclinical data from its immuno-oncology portfolio, including TNX-1700 and TNX-4700, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data were featured in one oral and two poster sessions, highlighting the company’s progress in developing novel cancer treatments.
The findings support TNX-1700’s potential in reducing inflammation and tumor progression in gastric cancer models, while demonstrating favorable pharmacokinetics. TNX-4700 showed promising in vitro activity targeting BTLA (B- and T-lymphocyte attenuator), a checkpoint receptor, underscoring its potential as a cancer immunotherapy candidate alone or in combination with other checkpoint inhibitors.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products Zembrace SymTouch and Tosymra. The company is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For more details on the presented data, visit the full press release at https://ibn.fm/Oly6o. The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
The presentation of these preclinical data is significant as it demonstrates Tonix’s continued progress in expanding its oncology pipeline, potentially addressing high unmet needs in gastric cancer and other malignancies. The positive results for TNX-1700 and TNX-4700 could lead to further development and clinical trials, offering new treatment options for patients.
